COMMUNIQUÉS West-GlobeNewswire

Tauriga Sciences, Inc. Shares Now Listed on OTCQB Marketplace; Up-List Effective at Open of Trading Monday July 30, 2018

30/07/2018 - 14:00

NEW YORK, NY, July 30, 2018 (GLOBE NEWSWIRE) -- Tauriga Sciences, Inc. (OTCQB: TAUG) (OTCQB: TAUGD) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of [...]

Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome

30/07/2018 - 14:00

Phase III Clinical Trial Ongoing at Multiple Sites in the U.S. REDWOOD CITY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company [...]

Apricus Biosciences, Inc. Announces Merger Agreement with Seelos Therapeutics, Inc. to Advance Late-Stage Pipeline of Products for Central Nervous System (CNS) Disorders

30/07/2018 - 14:00

Transaction to result in Nasdaq-listed company focused on developing novel products to treat central nervous system diseases Transaction expected to advance Seelos’ robust, late-stage pipeline of five programs, with [...]

BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management

30/07/2018 - 13:55

RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has [...]

Transactions under Novozymes’ stock buyback program

30/07/2018 - 13:46

Please read the full announcement in the attached PDF Attachment 2018_45_Stock_Buybackprogram_EN

Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019

30/07/2018 - 13:30

NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update [...]

Novo Nordisk A/S - Share repurchase programme

30/07/2018 - 13:22

Bagsværd, Denmark, 30 July 2018 - On 4 May 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]

Sienna Biopharmaceuticals Announces Pivotal Trials with SNA-001 in Acne Did Not Meet Primary and Secondary Endpoints

30/07/2018 - 13:05

-- Results from independent pivotal trials with SNA-001 for the reduction of unwanted light-pigmented hair expected beginning in the fourth quarter of 2018 -- Sienna continues to advance robust multi-asset pipeline, [...]

Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update

30/07/2018 - 13:00

XERMELO ® (telotristat ethyl) Quarterly U.S. Net Sales of $6.0 Million, Up 65% from Prior Year Quarter and 11% Quarter-Over-Quarter Filings for Regulatory Approval of Sotagliflozin in Type 1 Diabetes Accepted THE [...]

CLS Exhibits Thermal Therapy Laser Ablation System at AdMeTech Annual Conference

30/07/2018 - 13:00

Unique Non-Cooled Fiber Technology Optimizes Heat Distribution, Eliminates External Cooling, Reduces Procedure Times FRAMINGHAM, Mass., July 30, 2018 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc . ( [...]

Emerald Health Therapeutics’ Cannabis Joint Venture Pure Sunfarms Receives Sales License from Health Canada for 1.1 Million Square Foot Greenhouse

30/07/2018 - 13:00

Pure Sunfarms’ Delta 3 greenhouse facility becomes one of the largest Canadian cannabis growing operations licensed to sell product, with significant production and sales ramp expected through 2018 and beyond VANCOUVER [...]

RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn’s Disease

30/07/2018 - 13:00

Primary endpoint successfully achieved - superior remission rate at week 26 in patients treated with RHB-104 (p= 0.013) Key secondary endpoints also met, demonstrating consistent benefit to Crohn’s disease patients [...]

resTORbio to Present at the Canaccord Genuity 38th Annual Growth Conference

30/07/2018 - 13:00

BOSTON, July 30, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel [...]

Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team

30/07/2018 - 13:00

Appointments reflect transition to publicly-listed company status CHICAGO, July 30, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology [...]

Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian Distributor

30/07/2018 - 12:00

MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“ Company ”, “ GTG ”), a diversified molecular diagnostics company embracing blockchain technologies across [...]

Opthea Doses First Patient in Phase 2a Trial for OPT-302 in Diabetic Macular Edema

30/07/2018 - 12:00

MELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a late stage biopharmaceutical company developing novel biologic therapies to treat back-of-the eye diseases, has successfully dosed the [...]

The Ensign Group Schedules Second Quarter 2018 Earnings Call for Friday, August 3, 2018

30/07/2018 - 12:00

MISSION VIEJO, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care services, assisted living, home health [...]

Arrayit Corporation Signs Allergy Testing Contracts with a Nationwide Consortium of Medical Clinics

30/07/2018 - 11:30

Sunnyvale, July 30, 2018 (GLOBE NEWSWIRE) -- July 30, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, signs allergy testing contracts with a consortium of [...]

Kymab Announces Promising Results from Initial Clinical Study of New Antibody KY1005 for Treatment of Autoimmune Diseases

30/07/2018 - 10:00

Kymab Announces Promising Results from Initial Clinical Study of N ew Antibody KY1005 for Treatment of Autoimmune Diseases Top-line Phase I data demonstrated favorable safety, pharmacokinetics and pharmacodynamic [...]